Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.1-4 IBS is classified by its predominant bowel symptom: constipation (IBS-C), diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U).1 Since the exact cause of IBS is unknown, the goal of treatment is symptom control. Some over-the-counter (OTC) products and prescription drugs for IBS are listed in Tables 1-4. The safety of these drugs during pregnancy and lactation is described in Table 5.
...- Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
- Figure 1: Treatments for Irritable Bowel Syndrome (IBS) in Adults (online only)
- Comparison Chart: Some Drugs for Abdominal Pain in Irritable Bowel Syndrome (IBS) (online only)
- Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C) (online only)
- Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D) (online only)
- Valeda Light Delivery System for Age-Related Macular Degeneration
- Emrosi — Low-Dose, Biphasic Oral Minocycline for Rosacea
- Dupilumab (Dupixent) for COPD
- Seladelpar (Livdelzi) for Primary Biliary Cholangitis
- Zenocutuzumab (Bizengri) for NSCLC and Pancreatic Adenocarcinoma
- Zanidatamab (Ziihera) for Biliary Tract Cancer (online only)
RELEASE
The injectable glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide (Zepbound) has been approved by the FDA for treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. It is the first drug to be approved in the US for this indication. Zepbound is also approved for chronic weight management in adults with obesity and in those who are overweight and have at least one weight-related comorbidity.1 Tirzepatide is also available as Mounjaro for treatment of type 2 diabetes.2
STANDARD TREATMENT ― OSA is common in patients who are overweight and is a risk factor for cardiovascular disease. Positive airway pressure (PAP) therapy is the standard first-line treatment for OSA. It has been shown to improve the apnea-hypopnea index (AHI; the number of …